Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.54 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853241 | 0.96 | S1PR1 (0.53) | S1PR1S1PR4S1PR5HRH3ADORA3 | |
| SCHEMBL3855566 | 0.95 | S1PR1 (0.56) | S1PR1S1PR4S1PR5HRH3ADORA3 | |
| SCHEMBL3848347 | 0.90 | S1PR1 (0.55) | S1PR1S1PR4S1PR5HRH3ADORA3 | |
| SCHEMBL13713803 | 0.89 | S1PR1 (0.56) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL3848805 | 0.87 | S1PR1 (0.54) | S1PR1S1PR4S1PR5HRH3ADORA3 | |
| SCHEMBL3847474 | 0.87 | S1PR1 (0.57) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL3847503 | 0.87 | S1PR1 (0.48) | S1PR1S1PR4S1PR5HRH3S1PR3 | |
| SCHEMBL3851888 | 0.86 | HRH3 (0.53) | S1PR1S1PR5HRH3ADRA1DADRA1A | |
| SCHEMBL3849949 | 0.85 | HRH3 (0.52) | S1PR1S1PR5HRH3S1PR3ADRA1D | |
| SCHEMBL3847275 | 0.84 | S1PR1 (0.58) | S1PR1S1PR4S1PR5HRH3S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1921863-B | Immunosuppressant compounds and compositions | IRM LLC | 2013-04-03 | — | — | CN | claimed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | claimed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | claimed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | claimed |
| CN-1921863-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2007-02-28 | — | — | CN | claimed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | claimed |
| CN-1921863-B | Immunosuppressant compounds and compositions | IRM LLC | 2013-04-03 | — | — | CN | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| CN-1921863-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR4 211/4885S1PR5 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.